Researchers working at Lerner Research Institute, Cleveland Clinic reported in the November 8, 2021, issue of Nature Cancer that an inhibitor of the beta-amyloid producing enzyme, BACE1, could reprogram tumor-promoting M2 macrophages to exert M1 tumor-suppressing activities in animal models of glioblastoma multiforme.